Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q8VDJ3

Entry ID Method Resolution Chain Position Source
AF-Q8VDJ3-F1 Predicted AlphaFoldDB

49 variants for Q8VDJ3

Variant ID(s) Position Change Description Diseaes Association Provenance
rs3388489460 21 P>L No EVA
rs3388489051 22 Q>H No EVA
rs1134001941 134 D>Y No EVA
rs3412946968 254 T>P No EVA
rs3388489595 257 N>K No EVA
rs3388489928 279 Q>R No EVA
rs3388492832 309 Y>F No EVA
rs3388489437 311 I>S No EVA
rs3388491698 397 V>I No EVA
rs3388492061 403 E>V No EVA
rs3388492006 420 A>V No EVA
rs3388492805 430 D>N No EVA
rs3388490388 515 E>V No EVA
rs3388489450 530 I>T No EVA
rs3388492801 543 N>Y No EVA
rs3388489832 576 D>N No EVA
rs3388491235 584 I>V No EVA
rs3388489323 589 F>V No EVA
rs3388491757 590 K>E No EVA
rs3388489385 600 G>E No EVA
rs3388492940 606 K>N No EVA
rs3388489592 607 I>F No EVA
rs13465906 628 I>V No EVA
rs3388489300 629 I>F No EVA
rs3388489891 655 E>D No EVA
rs3388490369 677 R>H No EVA
rs3388490980 678 S>A No EVA
rs3388489067 690 F>Y No EVA
rs30377746 692 V>M No EVA
rs3388490400 765 A>T No EVA
rs3388492828 775 T>A No EVA
rs3388490983 799 N>T No EVA
rs3390254532 829 E>* No EVA
rs3388492040 904 N>K No EVA
rs3388491688 917 V>D No EVA
rs3388489830 1055 L>R No EVA
rs3388491095 1056 S>N No EVA
rs3388489930 1072 G>* No EVA
rs3388491030 1087 Q>* No EVA
rs3388491258 1108 K>E No EVA
rs3388489383 1139 H>Q No EVA
rs3388489613 1141 R>L No EVA
rs3388488901 1148 K>N No EVA
rs3388490382 1188 D>E No EVA
rs13465904 1220 R>K No EVA
rs3388492073 1222 P>S No EVA
rs3388489666 1231 A>T No EVA
rs3410540600 1242 P>A No EVA
rs3390353026 1243 D>H No EVA

No associated diseases with Q8VDJ3

28 regional properties for Q8VDJ3

Type Name Position InterPro Accession
domain K Homology domain 149 - 217 IPR004087-1
domain K Homology domain 221 - 289 IPR004087-2
domain K Homology domain 294 - 362 IPR004087-3
domain K Homology domain 363 - 429 IPR004087-4
domain K Homology domain 434 - 502 IPR004087-5
domain K Homology domain 506 - 575 IPR004087-6
domain K Homology domain 580 - 648 IPR004087-7
domain K Homology domain 652 - 721 IPR004087-8
domain K Homology domain 726 - 795 IPR004087-9
domain K Homology domain 799 - 868 IPR004087-10
domain K Homology domain 872 - 972 IPR004087-11
domain K Homology domain 973 - 1039 IPR004087-12
domain K Homology domain 1051 - 1122 IPR004087-13
domain K Homology domain 1126 - 1195 IPR004087-14
domain K Homology domain, type 1 154 - 212 IPR004088-1
domain K Homology domain, type 1 225 - 285 IPR004088-2
domain K Homology domain, type 1 298 - 357 IPR004088-3
domain K Homology domain, type 1 368 - 425 IPR004088-4
domain K Homology domain, type 1 438 - 498 IPR004088-5
domain K Homology domain, type 1 512 - 571 IPR004088-6
domain K Homology domain, type 1 584 - 644 IPR004088-7
domain K Homology domain, type 1 656 - 717 IPR004088-8
domain K Homology domain, type 1 732 - 791 IPR004088-9
domain K Homology domain, type 1 805 - 865 IPR004088-10
domain K Homology domain, type 1 877 - 968 IPR004088-11
domain K Homology domain, type 1 974 - 1033 IPR004088-12
domain K Homology domain, type 1 1056 - 1118 IPR004088-13
domain K Homology domain, type 1 1131 - 1191 IPR004088-14

Functions

Description
EC Number
Subcellular Localization
  • Cytoplasm
  • Nucleus
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

5 GO annotations of cellular component

Name Definition
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
cytosol The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
high-density lipoprotein particle A lipoprotein particle with a high density (typically 1.063-1.21 g/ml) and a diameter of 5-10 nm that contains APOAs and may contain APOCs and APOE; found in blood and carries lipids from body tissues to the liver as part of the reverse cholesterol transport process.
nucleus A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.
polysome A multiribosomal structure representing a linear array of ribosomes held together by messenger RNA. They represent the active complexes in cellular protein synthesis and are able to incorporate amino acids into polypeptides both in vivo and in vitro.

1 GO annotations of molecular function

Name Definition
mRNA binding Binding to messenger RNA (mRNA), an intermediate molecule between DNA and protein. mRNA includes UTR and coding sequences, but does not contain introns.

2 GO annotations of biological process

Name Definition
cholesterol metabolic process The chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. It is a component of the plasma membrane lipid bilayer and of plasma lipoproteins and can be found in all animal tissues.
lipid transport The directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lipids are compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.

5 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
P81021 HDLBP Vigilin Gallus gallus (Chicken) PR
Q24009 BicC Protein bicaudal C Drosophila melanogaster (Fruit fly) PR
Q00341 HDLBP Vigilin Homo sapiens (Human) PR
Q9Z1A6 Hdlbp Vigilin Rattus norvegicus (Rat) PR
P34307 C06G4.1 KH domain-containing protein C06G4.1 Caenorhabditis elegans PR
10 20 30 40 50 60
MSSVAVLTQE SFAEHRSGLV PQQIKVATLN SEEENDPPTY KDAFPPLPEK AACLESAQEP
70 80 90 100 110 120
AGAWSNKIRP IKASVITQVF HVPLEERKYK DMNQFGEGEQ AKICLEIMQR TGAHLELSLA
130 140 150 160 170 180
KDQGLSIMVS GKLDAVMKAR KDIVARLQTQ ASATVPIPKE HHRFVIGKNG EKLQDLELKT
190 200 210 220 230 240
ATKIQIPRPD DPSNQIKITG TKEGIEKARH EVLLISAEQD KRAVERLEVE KAFHPFIAGP
250 260 270 280 290 300
YNRLVGEIMQ ETGTRINIPP PSVNRTEIVF TGEKEQLAQA VARIKKIYEE KKKKTTTIAV
310 320 330 340 350 360
EVKKSQHKYV IGPKGNSLQE ILERTGVSVE IPPSDSISET VILRGEPEKL GQALTEVYAK
370 380 390 400 410 420
ANSFTVSSVS APSWLHRFII GKKGQNLAKI TQQMPKVHIE FTEGEDKITL EGPTEDVNVA
430 440 450 460 470 480
QEQIEGMVKD LINRMDYVEI NIDHKFHRHL IGKSGANINR IKDQYKVSVR IPPDSEKSNL
490 500 510 520 530 540
IRIEGDPQGV QQAKRELLEL ASRMENERTK DLIIEQRFHR TIIGQKGERI REIRDKFPEV
550 560 570 580 590 600
IINFPDPAQK SDIVQLRGPK NEVEKCTKYM QKMVADLVEN SYSISVPIFK QFHKNIIGKG
610 620 630 640 650 660
GANIKKIREE SNTKIDLPAE NSNSETIIIT GKRANCEAAR SRILSIQKDL ANIAEVEVSI
670 680 690 700 710 720
PAKLHNSLIG TKGRLIRSIM EECGGVHIHF PVEGSGSDTV VIRGPSSDVE KAKKQLLHLA
730 740 750 760 770 780
EEKQTKSFTV DIRAKPEYHK FLIGKGGGKI RKVRDSTGAR IIFPAAEDKD QDLITIIGKE
790 800 810 820 830 840
DAVREAQKEL EALIQNLENV VEDYMLVDPK HHRHFVIRRG QVLREIAEEY GGVMVSFPRS
850 860 870 880 890 900
GTQSDKVTLK GAKDCVEAAK KRIQEIIEDL EAQVTVECAI PQKFHRSVMG PKGSRIQQIT
910 920 930 940 950 960
RDYNVQIKFP DREENPVHSV EPSIQENGDE AGEGREAKET DPGSPRRCDI IIISGRKEKC
970 980 990 1000 1010 1020
EAAKEALEAL VPVTIEVEVP FDLHRYIIGQ KGSGIRKMMD EFEVNIHVPA PELQSDTIAI
1030 1040 1050 1060 1070 1080
TGLAANLDRA KAGLLDRVKE LQAEQEDRAL RSFKLSVTVD PKYHPKIIGR KGAVITQIRL
1090 1100 1110 1120 1130 1140
EHEVNIQFPD KDDGNQPQDQ ITITGYEKNT EAARDAILKI VGELEQMVSE DVPLDHRVHA
1150 1160 1170 1180 1190 1200
RIIGARGKAI RKIMDEFKVD IRFPQSGAPD PNCVTVTGLP ENVEEAIDHI LNLEEEYLAD
1210 1220 1230 1240 1250 1260
VVDSEALQVY MKPPAHEESR APSKGFVVRD APWTSNSSEK APDMSSSEEF PSFGAQVAPK
TLPWGPKR